natgillin/translations-raw huggingface dataset:
the ceftriaxone or said pharmaceutically acceptable salt thereof, is present in an amount of about 1 g, calculated as ceftriaxone free acid, 
(a) ceftriakson natrij u količini od 1 g, preračunato kao ceftriaksonska slobodna kiselina,
The injector of any one of claims 1 to 12, wherein the actuator is adapted to delay movement of the container needle from the storage state to the delivery state after an input is received. 
Ubrizgač prema bilo kojem od prethodnih zahtjeva, naznačen time, što je pokretač (456) prilagođen da odgodi kretanje igle spremnika (550, 702, 772) iz pasivnog stanja u stanje za isporuku nakon primanja unosa.
where the azetidine may have two substituents which, together with the carbon atom of the azetidine to which they are jointly attached, form an oxetane, and the salts thereof, the solvates thereof and the solvates of the salts thereof. 
R' i R* zajedno s dušikovim atomom na koji su oni vezani tvore azetidin, gdje azetidin može imati dva supstituenta koji, zajedno s ugljikovim atomom iz azetidina na koji su zajednički vezani, tvore oksetan,
The user can position himself in the location that is best for estimating the distance to the dock or to another boat, thus enhancing the accuracy of the maneuver. 
Korisnik se može postaviti na mjesto s kojeg je najbolje moguće procijeniti udaljenost do pristajališta ili drugog plovila, i tako povećati preciznost samog manevra.
The compound for use of embodiment 8, wherein the subject suffers from neurodegeneration with brain iron accumulation. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što subjekt boluje od neurodegeneracije uz nakupljanje željeza u mozgu.
A process for preparing cross-linked polymers or salts thereof comprising a repeating unit of Formula (I), and/or Formula (II), wherein n is an integer and X- is an inorganic or organic pharmaceutically acceptable anion, such as halide, phosphate, phosphite, carbonate, bicarbonate, sulphate, bisulfate, hydroxide, nitrate, persulfate, sulfite, sulphide, acetate, ascorbate, benzoate, citrate, dihydrogen citrate, hydrogen citrate, oxalate, succinate, tartrate, taurocholate, glycocholate, or cholate; 
(ll) naznačen time da n je cijeli broj i X je anorganski ili organski farmaceutski prihvatljiv anion, kao halid, fosfat, fosfit, karbonat, bikarbonat, sulfat, bisulfat, hidroksid, nitrat, persulfat, sulfit, sulfid, acetat, askorbat, benzoat, citrat, dihidrogen citrat, hidrogen citrat, oksalat, sukcinat, tartrat, taurokolat, glikokolat, ili kolat; koji postupak sadrži: reakciju alilamina u prisutnosti kiseline sa sredstvom za umrežavanje prema formuli (TV)
A pharmaceutical composition of claim 17, further comprising a pharmaceutically acceptable diluent or carrier. 
Farmaceutski sastav prema zahtjevu 18, naznačen time, da dodatno obuhvaća farmaceutski prihvatljiv razrjeđivač ili nosač.
The crystalline Form A of N -methyl-1-{trans -4-[methyl(7 H -pyrrolo[2,3- d]pyrimidin-4-yl)amino]cyclohexyl}methanesulfonamide maleic acid salt according to claim 4 or 5, which comprises an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at approximately, 6.2, 12.6, 15.7, 18.5, 27 and 28.38. 
Kristalni Oblik A soli N-metil-1-{trans-4-[metil(7H-pirolo[2,3-d]pirimidin-4-il)amino]cikloheksil}metansulfonamida s maleinskom kiselinom u skladu s patentnim zahtjevom 4 ili 5, naznačen time što njegov uzorak difrakcije rendgenskih zraka na prahu ima karakteristične signale, izražene u stupnjevima 2θ, na otprilike, 6,2, 12,6, 15,7, 18,5, 27 i 28,38.
The support device for supporting the mould plate may be carried out in several ways, for instance with support legs which are directly connected to the mould plate. Preference is given to an embodiment wherein the support device comprises beams, pipes or bars which extend generally parallel beneath the mould plate, each bar being supported by means of at least two extendable and retractable support legs. 
Sustav kalupa u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu potporna naprava (5) obuhvaća stupce (10) koji se uglavnom produžuju paralelno ispod ploče kalupa (10), svaki je stupac poduprt pomoću barem dvije potporne noge (8) koje se mogu produljiti 1 uvući podešavanjem pod nadzorom računala,
The two enclosing members can at least partially pinch a portion of the sealing material and a flange-like rim of the capsule. 
Dva elementa koji obuhvaćaju čahuru mogu barem djelomično stisnuti dio s materijalom za brtvljenje i rub čahure koji ima oblik prirubnice.
immunising the non-human transgenic mammal of claim 1 with the antigen, wherein the mammal expresses heavy chain-only antibodies which lack CH1 functionality in the transcribed and processed heavy chain mRNA; isolating long-lived plasma cells or memory B-cells from the immunised mammal; 
(a) imuniziranje ne-humanog transgenog sisavca s antigenom, pri čemu sisavac eksprimira antitijela koja sadrže samo teški lanac kojima nedostaje CH1 domena u transkribiranoj i obrađenoj mRNA teškog lanca, te pri čemu su antitijela koja sadrže samo teški lanac eksprimirana iz transgenog lokusa sisavca;
Particularly preferred are the compounds (I) wherein: 
Posebno su preferirani su spojevi (I) u kojima:
Carbonyl linkers may be in the 31 position, the 42 position, or both. 
Karbonilni veznici mogu biti na položajima 31, 42 ili oboje.
A monoclonal antibody or antigen-binding fragment thereof that binds human CGRP receptor, wherein the monoclonal antibody or antigen-binding fragment thereof selectively inhibits the human CGRP receptor as compared with human AM1, AM2, and AMY1 receptors with a selectivity ratio of 100 or more as determined by a cAMP inhibition assay. 
Antitijelo ili njegov antigen-vežući fragment prema patentnim zahtjevima 1 ili 2, naznačeno time što je antitijelo ili antigen-vežući fragment odabrano iz grupe koja se sastoji od monoklonskog antitijela, Fab fragmenta, Fab’ fragmenta, F(ab’)2 fragmenta, Fv fragmenta, di-antitijela i jednolančanog antitijela.
The present invention is also directed to a use of both a compound of formula I and another type of antidiabetic agent and/or another type of therapeutic agent, such as a hypolipidemic agent, in the manufacture of a medicament for treating the diseases as defined above and hereinafter in a human patient. 
Ovaj izum je također usmjeren na primjenu spoja formule I i drugog tipa antidijabetičnog sredstva i/ili drugog tipa terapeutskog sredstva, kao što je hipolipidemijsko sredstvo, u proizvodnji lijeka za liječenje bolesti kao što je definirano u prethodnom tekstu i u daljnjem tekstu kod humanog pacijenta.
is selected from II, optionally substituted C1-C8 alkyl, optionally substituted C2-C8 alkenyl, optionally substituted C2-C8 alkynyl, optionally substituted C6-C 12 aryl, optionally substituted C6-C16 aryl C1-C8 alkyl, optionally substituted hetero C5-C10 aryl, optionally substituted C3-C10 cycloalkyl, and optionally substituted hetero C3-C10 cycloalkyl, wherein said optional substituents are one to three R10 groups; 
R* je odabran od H, proizvoljno supstituiranog C,-Ca alkila, proizvoljno supstituiranog C>-Cg alkenila, proizvoljno supstituiranog C2-Cg alkinila, proizvoljno supstituiranog Cs-C;2 arila, proizvoljno supstituiranog Cg-Cig arila Cy-Cg alkila, proizvoljno supstituiranog hetero Cs-C;o arila, proizvoljno supstituiranog Ca-Cyo cikloalkila i proizvoljno supstituiranog hetero C3-C, cikloalkila, pri čemu su navedeni nezavisni supstituenti jedna do tri R'" skupine;
An oligonucleotide decoy consisting of the sequence of SEQ ID NO: 41. 
Oligonukleotidna zamka, naznačena time, da se sastoji od sekvence od SEQ ID NO:41.
A vaccine comprising a nucleic acid sequence encoding an HIV gp140 trimer of any one of claims 1 to 7. 
Cjepivo sadrži sekvence nukleinske kiseline koja kodira HIV gp 140 trimer sukladno zahtjevima 1 – 7.
12, the foil member 5 can be wrapped (see reference 27) over the rim of the capsule. FIG. 13 and FIG. 
Kao što se može naročito vidjeti iz slike 12, element od folije 5 može biti pokidan (vidi oznaku 27) na rubu čahure.
In some embodiments, the biologically active molecule or imaging agent is non-covalently bound to the carrier peptide. 
Kompleks prema zahtjevu 5, naznačen time da je biološki aktivna molekula ili kontrastno sredstvo nekovalentno vezano na peptid nosač.
An inhaler according to claim 1, wherein the inhaler is a breath-actuated metered-dose inhaler. 
Inhalator u skladu s bilo kojim prethodnim patentnim zahtjevom, pri čemu je inhalator disanjem-potaknuti inhalator s mjerenjem doze.
Fungicidal composition and method for controlling plant diseases 
FUNGICIDNI PRIPRAVAK I POSTUPAK ZA KONTROLIRANJE BOLESTI BILJAKA
detecting hybridization of the probe to the DNA. 
otkrivanje hibridizacije DNA proba.
A unit dose of 0.5ml of an aqueous pharmaceutical solution which contains in solution 20mg glatiramer acetate and 20mg mannitol. 
Jedinična doza od 0,5 ml vodene farmaceutske otopine naznačena time, da u otopini sadrži 20 mg glatiramer acetata i 20 mg manitola.
In this regard, the at least one filament may comprise textured polyester or Lycra or a similar material. 
S obzirom na to najmanje jedna nit može sadržavati teksturirani poliester ili Lycra" ili neki drugi slični materijal.
In some embodiments, R1 is F. in some embodiments, R1 is H. 
U nekim oblicima R, je F. u nekim oblicima Ri je H.
The process of claim 1, wherein the suitable chlorooxime formation conditions comprise adding HCI in dioxane to a solution of the oxime in the presence of N-chlorosuccinimide (NCS) in a suitable solvent selected from DCM, dichloroethane (DCE), tetrahydrofuran (THF), dioxane, an aromatic hydrocarbon, or an alkyl acetate. 
15 5. > Postupak u skladu s patentnim zahtjevom 4, naznačen time, da pogodni uvjeti stvaranja klorooksima obuhvaćaju dodavanje HCI u dioksanu otopini spoja formule 4-i u prisutnosti NCS-a u pogodnom otapalu odabranom od neprotonskih otapala, aromatskih ugljikovodika i alkil acetata.
the driving means (30) of the mass are extended along the direction of a single axis (X); 
- pogon (30) mase se pruža u smjeru jedne osi (X);
effecting a nitration reaction of the compound prepared in step (a) with a nitrating agent in the presence of a carboxylic anhydride, preferably acetic anhydride. 
H-o i (b) nitriranje spoja proizvedenog u stupnju (a) sa sredstvom za nitriranje u prisutnosti karboksilnog anhidrida, ponajprije octenog anhidrida.
The bandage of claim 1 comprising a layer of cotton gauze and a layer of dried, lanthionized, ion-exchanged keratin material. 
Zavoj u skladu sa zahtjevom 18, naznačen time, što obuhvaća sloj pamučne gaze i osušeni sloj, lantioniziranog, ion-izmjenjenog keratin materijala.
About 1 % w/w of CSGS 10A was mixed in the above mentioned PU-acrylate dispersion and the conductive flooring was coated with approx 20 g/m2 in a roller coating station. 
Oko 1 % težinskog udjela CSGS 10A pomiješa se u gore navedenu PU-akrilnu disperziju i vodljiva podna obloga se premaze s približno 20 g/m2 u pogonu za nanošenje valjcima.
Pipet a 5.0 mL portion of the clear solution into a 100-ml volumetric flask, dilute to volume with water, and mix. 
Odpipetira se 5,0 mL dio bistre otopine u 100 ML volumetrijsku tikvicu, razrijedi do volumena s vodom, i pomiješa.
The method of any one of claims 1-8 wherein the composition is loaded onto the chromatography material at about the dynamic binding capacities of the chromatography materials for the one or more contaminants. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time da se sastav puni u kromatografski materijal pri otprilike dinamičkim kapacitetima vezivanja kromatografskih materijala za jednog ili više kontaminanata.
at least one cell consisting of: two cation exchange membranes defining a chamber for the at least partly AX-REED treated liquid; and 
najmanje jednu ćeliju koja se sastoji od: a. dvije membrane za izmjenu kationa koje definiraju komoru za početnu tekućinu ili djelomično obrađenu tekućinu s AX-REED; i b.
For example, the particle size of the drug substance affects drug product manufacturing and dissolution and hence its bioavailability. 
Na primjer, veličina čestica ljekovite tvari utječe na preradu ljekovitog produkta i na otapanje te stoga na njegovu biodostupnost.
In another embodiment the present disclosure provides a method of enhancing, stimulating, and/or increasing the immune response in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a therapeutically acceptable salt thereof. 
Spoj iz patentnog zahtjeva 1 ili njegova terapijski prihvatljiva sol za primjenu u poboljšanju, stimuliranju, i/ili povećavanju imunološkog odgovora kod subjekta kod kojeg postoji potreba za tim.
Most patients with recurrent candidiasis can be managed with intermittent prophylactic treatment with a single dose or multiple doses of topical or oral antifungals given to prevent symptomatic episodes. 
Većinu pacijenata s recesivnom kandidijazom može se držati pod kontrolom s isprekidanim preventivnim liječenjem s jediničnom dozom ili višestrukim dozama anti-gljivičnih lijekova koji se daju da se spriječe simptomatske epizode.
The solution is filtered and the solvent is removed in vacuo. 
Otopinu se profiltrira i otapalo se odstrani u vakuumu.
Accordingly, the present invention provides methods of treating a subject suffering from a disorder associated with hyperlipidemia while reducing side-effects, the method comprising the step of administering to the subject an effective amount of the MTP inhibitor to ameliorate hyperlipidemia and/or hypercholesterolemia in the subject according to a treatment regimen that reduces and/or eliminates side-effects associated with the use of the inhibitors. 
HR P20130115 T1 PATENTNI ZAHTJEVI Uporaba inhibitora MTP u proizvodnji lijeka za liječenje subjekta koji pati od poremećaja povezanog sa hiperlipidemijom i/ili hiperkolesterolemijom, naznačen time što navedeno liječenje sadrži primjenu najmanje tri postepeno rastuće doze navedenog inhibitora MTP na navedenog subjekta,
Number of Patients: 
Broj međunarodne prijave:
A multicomponent microbicidal contraceptive intravaginal ringed-mesh device as in claim 3 wherein the ring matrix contains microparticulates of ferrous gluconate, ascorbic acid, glycine, and polyglycolic acid and wherein the polymeric coating contains at least one bioactive agent selected from the group consisting of antibacterial agents, antifungal agents, antiviral agents, antiretroviral agents, antineoplastic agents, anti-inflammatory agents. 
Uređaj u vidu višekomponentne mikrobicidne kontraceptivne intravaginalne prstenaste mrežice u skladu s patentnim zahtjevom 1, naznačen time što matriks prstena sadrži mikročestice fero glukonata, askorbinske kiseline, glicina, te poliglikolne kiseline, te što polimerna obloga sadrži najmanje jedno od navedenih bioaktivnih sredstava, koja se bira iz skupine koju čine antibakterijska sredstva, antifungalna sredstva, antivirusna sredstva, antiretrovirusna sredstva, antineoplastična sredstva, protuupalna sredstva.
The preparation method according to any of claims 3-8, wherein following the addition of the acetate, the reaction mixture is heated to 30-50°C, resulting in a clear solution; the said solution is then left to cool on its own, and water is added dropwise in order to bring about crystallization. 
Postupak pripreme u skladu s bilo kojim od patentnih zahtjeva 2 do 7, naznačen time, da se nakon dodavanja acetata, reakcijska smjesa zagrijava do 30 do 50 °C, što rezultira bistrom otopinom; navedenu otopinu se ostavi da se sama ohladi i dodaje se voda kap po kap kako bi se postigla kristalizacija.
The method of claim 14, wherein the Crenolanib or a salt thereof is provided as a single agent in treatment of patients with the hematologic malignant neoplastic disorder that is either refractory to, or has relapsed after prior treatment with a chemotherapeutic agent. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 13, pri čemu se crenolanib ili njegova sol osigurava kao jedini agens u liječenju subjekata s akutnom mijeloičnom leukemijom (AML) koja je ili refraktorna ili je relapsirala nakon prethodnog liječenja kemoterapijskim agensom.
granulating the raw materials from step (1) using a dry granulation process, wherein the apixaban particles have a mean particle size equal to or less than about 85 µm and a D90 equal to or less than 85 µm; 
granulacija sirovih materijala iz koraka (1) primjenom procesa suhe granulacije, pri čemu čestice apiksabana imaju D90 manji od 89 µm kao što je mjereno sa rasipanjem laserske svjetlosti;
is a direct-bonded or oxygen-linked saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, but containing no more than one O or S, wherein the available carbon atoms of the ring are substituted by 0, 1 or 2 oxo or thioxo groups, wherein the ring is substituted by 0 or 1R2 substituents, and the ring is additionally substituted by 0, 1, 2 or 3 substituents independently selected from halo, nitro, cyano, C1-4alkyl, OC1-4alkyl, OC1-4haloalkyl, NHC1-4alkyl, N(C1-4alkyl)C1-4alkyl and C1-4haloalkyl; 
R' je direktno vezan ili preko kisika vezan zasićen, djelomično zasićen ili nezasićen 5-, 6- ili 7-člani monociklični prsten koji sadrži 0, 1, 2, 3 ili 4 atoma izabrana od N, O 1 S, ali koji sadrži ne više od jednog O ili S, gdje su dostupni atomi ugljika u prstenu supstituirani sa 0, 1 ili 2 okso ili tiokso grupe, gdje je prsten supstituiran sa 0 ili 1 R? supstituenta, i prsten je dodatno supstituiran sa 0, 1, 2 ili 3 supstituenta nezavisno izabrana od halo, nitro, cijano, Ci. aalkil, OC,alkil, OC, ghaloalkil, NHC,alkil, N(C,galkiDC,alkil i C,aghaloalkil;
Another option for preventing abuse of the dosage form according to the invention consists in adding at least one viscosity-increasing agent as a further abuse-preventing component (b) to the dosage form, which, with the assistance of a necessary minimum quantity of an aqueous liquid, forms a gel with the extract obtained from the dosage form, which gel is virtually impossible to administer safely and preferably remains visually distinguishable when introduced into a further quantity of an aqueous liquid. 
Daljnja mogućnost da se kod oblika davanja prema izumu spriječi zlouporaba se sastoji u tome, da se obliku davanja doda barem jedno sredstvo za povećanje viskoziteta kao daljnja komponenta (b) koja sprečava zlouporabu, koje sredstvo pomoću potrebne najmanje količine vodene tekućine, prvenstveno kao vodenog ekstrakta dobivenog iz oblika davanja, stvara gel, koji se teško može bezopasno aplicirati, a prvenstveno se kod unošenja u daljnju količinu vodene tekućine može vizualno razlikovati.
Preferably, the curing step starts according to method 3, when the temperature of the extended release matrix formulations reaches a curing temperature of at least about 62 °C, at least about 68 °C or at least about 70 °C, more preferably, of at least about 72 °C or at least about 75 °C. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da, formulacija matrice s produljenim otpuštanjem ima snagu pucanja od barem oko 120 N, od barem oko 130 N ili od barem oko 140 N i/ili,,dubinu prodiranja s razmakom pukotine" od barem oko 1.2 mm, poželjno od barem oko 1.4 mm, od barem oko 1.5 mm ili od barem oko 1.6 mm.
Wind system (1) according to claim 1, characterised in that said frictioning system is equipped with at least one pulley constrained to a linear guide and at least one spring constrained next to an end to said pulley and next to another end to a trolley (11). 
Vjetreni sustav (1) prema zahtjevu 1, naznačen time da je spomenuti sustav za trenje opremljen barem jednim koloturnikom pričvršćenim na linearnu vodilicu 1 barem jednom oprugom koja je na jednom kraju pričvršćena na spomenuti koloturnik a na drugom kraju na spomenuta kolica (11).
The method according to claim 11, wherein R2 is -CH2-. 
Postupak u skladu sa zahtjevom 11, naznačen time, da R2 je -CH2-.
The assembly according to claim 7, wherein said elongated flexible body is at least 18 inches long. 
Sklop u skladu s patentnim zahtjevom 1, naznačen time što je navedeno izduženo savitljivo tijelo dugačko najmanje 45,72 cm (18 inča).
In another embodiment, the invention provides a compound according to Formula (II): 
5 21. Spoj naznačen time da ima formulu (II):
a N-oxide form, an addition salt or a stereochemically isomeric form thereof, wherein m is 0, 1, or 2 and when m is 0 then a direct bond is intended; 
|, (D njegov N-oksidni oblik, adicijska sol ili stereokemijski izomerni oblik, naznačen time, da m je 0, 1, ili 2 ikada m je 0 tada je namjeravana direktna veza;
wherein said antisense oligonucleotide is complementary to human dystrophin pre-mRNA to induce exon 55 skipping, and a pharmaceutically acceptable carrier. A composition for use according to claim 17, wherein the oligonucleotide is conjugated to a polyethylene glycol chain. 
Protusmisleni oligonukleotid ili njegova farmaceutski prihvatljiva sol prema zahtjevima 1-4, naznačen time što je oligonukleotid konjugiran na lanac polietilen glikola vezan preko supstituiranog dijela piperazinila.
obtaining sound propagation parameters, including speed and attenuation, in various pipe sections of the pipeline by processing composite signals; and evaluating a correlation of the vibroacoustic measurements between adjacent measurement stations, wherein the signal to be processed includes both the acoustic noise generated by the pig device moving along the pipeline and pressure variations in the fluid. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što uključuje korak dobivanja parametara širenja zvuka, koje čine brzina i prigušenje, u različitim cijevnim odjeljcima cjevovoda (12) obradom složenih signala, procjenjivanja korelacije vibroakustičnih mjerenja između susjednih mjernih postaja (14), gdje se xn) = HR P20171911 T1 signal koji treba obraditi sastoji i od akustične buke koju generira prasica (10) dok se kreće po cjevovodu (12) i od varijacija tlaka u fluidu.
For nebivolol test & reference formulations the mean Cmax achieved was 2.605±0.66 ng/ml and 2.574±0.78 ng/ml respectively. 
Za nebivolol test & referentni pripravaka srednja Cux postignuta bila je 2,605 + 0,66 ng/l i 2,574 + 0,78 ng/ml.
A compound according to claim 1, wherein the heteroatom is N in the 5-membered ring formed by R5 and R6 together. 
Spoj prema patentnom zahtjevu 1, gdje heteroatom je N u 5-članom prstenu formiranom pomoću R? i R5 zajedno.
A compound according to any one of the preceding claims, wherein the pharmaceutically acceptable salt is selected from the group consisting of the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, isonicotinate, acetate, lactate, salicylate, citrate, tartrate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzensulfonate, p-toluenesulfonate and pamoate. 
Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time da je farmaceutski prihvatljiva sol odabrana iz skupine koju čine hidroklorid, hidrobromid, hidrojodid, nitrat, sulfat, bisulfat, fosfat, kiseli fosfat, izonikotinat, acetat, laktat, salicilat, citrat, tartrat, pantotenat, bitartrat, askorbat, sukcinat, maleat, gentisinat, fumarat, glukonat,
at least one coupling device (6) which blocks internal movements of the epicyclic gear (3) in a first rotational direction and permits the internal movements in an opposite rotational direction, 
unutarnje kretanje epicikličkog planetarnog prijenosnika (3) je blokirano u jednom smjeru rotacije i dopušteno u drugom smjeru rotacije, pri čemu
a hybridoma deposited under the accession no. 
hibridoma deponiranog pod pristupnim br.
providing a population of lymphocytes or T-cells, obtained from a subject and, optionally enriching or isolating and propagating, a population of lymphocytes or T-cells; 
osiguravanje populacije limfocita ili T stanica, dobivenih iz subjekta i, opcijski obogaćivanje ili izoliranje i razmnožavanje, populacije limfocita ili T stanica;